Hoth Therapeutics, Inc., a biopharmaceutical company, completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and has received orphan drug designation from the U.S. FDA. Hoth also recently completed its Pre-IND meeting with the FDA in November. Hoth has now successfully completed manufacturing of the HT-KIT drug substance in collaboration with WuXi...